Clinical trials: Alzheimer's Type
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild and Moderate Alzheimer's Disease, Cognitively Healthy People
An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population
- Trial name
- NCT02249468
- Where
- Singapore
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Danone Nutricia Research
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer's Type Dementia
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
- Trial name
- NCT01404169
- Testing
- E2020
- Where
- 32 sites in China
- Volunteers
- 260 people
- Sponsor
- Eisai Limited
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Dementia, Alzheimer Type
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
- Trial name
- NCT01438060
- Testing
- Aripiprazole (BMS-337039)
- Volunteers
- 232 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00036114
- Testing
- aripiprazole
- Where
- 41 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation Associated With Dementia of the Alzheimer's Type
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the…
- Trial name
- NCT03620981
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 410 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
- Trial name
- NCT00130429
- Testing
- PYM50028
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Phytopharm
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer's Disease
Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
The purpose of this study is to evaluate the efficacy and safety of galantamine in patients who failed to benefit from donepezil (patients switching from donepezil).
- Trial name
- NCT01478633
- Testing
- Galantamine
- Where
- 11 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Severe Alzheimer's Disease
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
A 12-week, multicenter, randomized, double-blind, placebo-controlled phase IV study. Approximately 200 subjects will be enrolled, half will receive active drug (donepezil hydrochloride) and half will receive matching placebo at…
- Trial name
- NCT00711204
- Testing
- Donepezil Hydrochloride (Aricept)
- Where
- United States
- Sponsor
- Eisai Inc.
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Alzheimer Disease, Dementia of Alzheimer Type
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
- Trial name
- LIFT-AD (NCT04488419)
- Testing
- ATH-1017
- Where
- United States
- Volunteers
- 554 people
- Sponsor
- LeonaBio
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- ACCORD-2 (NCT04947553)
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 456 people
- Sponsor
- Axsome Therapeutics, Inc.
Cognitive Dysfunction, Dementia, Mild
FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Trial name
- NCT05504811
- Testing
- FitMi AD, Conventional exercise program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Flint Rehabilitation Devices, LLC